Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/9/2021 (updated 4/10/2024)
Background: Racial/ethnic disparities in the use of opioids to treat pain disorders have been previously reported in the emergency department (ED). Further research is needed to better evaluate the impact race/ethnicity may have on the use of opioids in adolescents for the management of pain disorders in the ED.
Posted 12/29/2020 (updated 4/4/2024)
An analysis of emergency department data shows a rise in nonfatal drug overdoses for youth under 15, from 2016 to 2019. Overdoses among the youngest kids aged 0-14 are relatively rate. However, risk increases with age, as the rate of all drug overdoses among youth aged 15-24 was more than double that of 11-14-year olds. Stimulant overdoses increased for all age groups, while heroin decreased for 15-24-year olds.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.
Posted 6/17/2021 (updated 4/2/2024)
Fueled by misinformation, fentanyl panic has harmed public health through complicating overdose rescue while rationalizing hyper-punitive criminal laws, wasteful expenditures, and proposals to curtail vital access to pain pharmacotherapy. To assess misinformation about health risk from casual contact with fentanyl, we characterize its diffusion and excess visibility in mainstream and social media.
Posted 4/6/2020 (updated 3/28/2024)
Opioid overdose death rates were reduced in communities where overdose education and nasal naloxone distribution (OEND) was implemented. This study provides observational evidence that by training potential bystanders to prevent, recognize, and respond to opioid overdoses, OEND is an effective intervention.
Posted 1/26/2024 (updated 3/28/2024)
This study links parental incarceration to adolescent substance use in rural communities. The data is state-specific and pulls from the 2019 Minnesota Student Survey in which adolescents self-reported experiences. Results concluded that parental incarceration was associated with higher substance use and expanded prevention and intervention strategies for adolescents could help reduce the rates.
Posted 3/21/2023 (updated 3/27/2024)
Researchers at Indiana University conducted one-on-one interviews with clinical providers and other stakeholders in the recovery arena to better understand the slow uptake of the drug most used to treat opioid use disorder. Biases against buprenorphine was the most consistent theme, though the reason for bias differed amongst stakeholders. Clinical providers and behavioral health care providers preferred the abstinence approach rather than use of medications.
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 3/9/2022 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) together with leading clinicians, researchers, and policy experts led the development of a standard clinical definition for opioid withdrawal in infants to help improve care. It is accompanied with a set of foundational principles that outlines bioethical uses for the definition, distinctly centering around identifying clinical and supportive care needs of mothers and their infants, using an evidence-based, compassionate, and equitable approach.
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.